Patients with pancreatic cysts can be monitored for years, yet cancer may still appear at an advanced stage. This study asks whether blood markers and imaging show a recognizable warning trajectory before diagnosis. Trajectories of serological and morphological signatures have not been documented in pancreatic carcinogenesis related to intraductal papillary mucinous neoplasms, or IPMNs.

That missing evidence is the central problem: trajectories of serological and morphological signatures had not been documented during pancreatic carcinogenesis related to intraductal papillary mucinous neoplasms. An intraductal papillary mucinous neoplasm of the pancreas is a papillary lesion arising from the pancreatic epithelium, and it can potentially progress to pancreatic cancer.

Patients with IPMNs are also at high risk of developing concomitant pancreatic ductal adenocarcinoma, or PDAC, meaning a separate pancreatic cancer alongside the IPMN. Because IPMNs are largely indolent, most patients undergo surveillance based on abdominal imaging studies.

Yet surveilled patients are occasionally diagnosed with pancreatic cancer at an advanced, noncurable stage. The study therefore focuses on alterations in serological and morphological characteristics during carcinogenesis, with the goal of designing effective surveillance programs for early diagnosis.

Cross-sectional studies have extensively documented morphological features of IPMNs that are highly suggestive of pancreatic cancer development. International consensus guidelines proposed worrisome features and high-risk stigmata as predictive factors for carcinoma lesions in surgical IPMN specimens.

But because long-term follow-up data were scarce, the morphological progression of IPMNs before pancreatic carcinoma diagnosis was not well characterized. The study used one hundred patients diagnosed with pancreatic carcinomas inside a large prospective cohort, whose follow-up duration reached up to twenty-five years.

It examined when CA19-9, HbA1c, and pancreatic enzymes became abnormally elevated, and when worrisome features or high-risk stigmata appeared before clinical diagnosis. The prospectively maintained database collected consecutive patients with pancreatic cystic lesions, including IPMNs, at The University of Tokyo Hospital in Tokyo, Japan.

IPMN diagnoses were based on imaging findings according to the International Association of Pancreatology consensus guideline proposed in twenty seventeen. Among patients diagnosed with IPMNs from January nineteen ninety-four through August twenty twenty-two, the study included pancreatic carcinoma patients with available prediagnosis information.

Patients were followed until death or the end of follow-up on September thirtieth, twenty twenty-two, and several baseline and missing-data exclusions were applied. Patients visited the outpatient clinic every six months for physical examinations and blood tests, including CA19-9, CEACAM5, HbA1c, and amylase; pancreatic amylase and lipase were measured at physicians’ discretion.

At the same interval, imaging included magnetic resonance imaging with magnetic resonance cholangiopancreatography, along with abdominal ultrasound, endoscopic ultrasound, and contrast-enhanced computed tomography. The clinical cohort included four thousand four hundred sixty-one patients with pancreatic cysts, including three thousand four hundred thirty-seven IPMN patients under long-term surveillance.

During nineteen thousand seven hundred ninety-five person-years of IPMN follow-up, the study documented one hundred pancreatic carcinoma cases. Median follow-up was five point seven years, ranging from zero point five to twenty-five point six years.

The one hundred cases were evenly divided: fifty IPMN-derived carcinomas and fifty concomitant carcinomas. Table one summarizes the one hundred pancreatic carcinoma cases identified during long-term surveillance of IPMN patients, split evenly between IPMN-derived and concomitant carcinomas.

It compares demographics, symptoms, laboratory markers, tumor location, main pancreatic duct diameter, and clinical stage. Most characteristics have similar group distributions, while HbA1c, CA nineteen-nine, duct diameter, and clinical stage show reported P values of zero point zero four, zero point zero zero two, zero point zero three, and less than zero point zero zero one, respectively.

At diagnosis, elevated CA19-9, HbA1c, and pancreatic enzymes were observed in thirty-nine, three, and eighteen patients, respectively. All listed items showed no aberrant elevation in forty-eight patients. Follow-up imaging showed abnormal findings suggesting pancreatic carcinoma development in eighty-two patients, including development or progression of a mural nodule or development of a solid mass.

Among the ten patients without abnormal imaging findings, all had undergone abdominal ultrasound, and nine, or ninety percent, had elevated CA19-9 that prompted further evaluation and immediate carcinoma diagnosis. Because HbA1c elevation occurred in very few patients, its prediagnostic trajectory was not examined.

Figure three tracks serum CA19-9 measurements backward from pancreatic carcinoma diagnosis, with each horizontal bar representing a patient and colors marking levels from within normal limits to at least five times the reference value. The two panels separate IPMN-derived carcinomas from concomitant pancreatic ductal adenocarcinomas, while the side bands show age, sex, main pancreatic duct size, and cancer stage.

The authors report elevated CA19-9 in sixty percent of concomitant cases versus thirty percent of IPMN-derived cases, highlighting its different longitudinal pattern across these carcinoma types. CA19-9 elevation was observed in thirty-nine patients and was associated with a metastatic stage.

Compared with IPMN-derived carcinomas, concomitant carcinomas were more likely to show CA19-9 elevation: sixty percent versus thirty percent. For IPMN-derived carcinomas, CA19-9 elevation occurred in twenty-three percent of stage zero to two cases versus seventy-one percent of stage three to four cases.

For concomitant PDACs, the corresponding figures were forty-one percent and one hundred percent. The aberrant-elevation group had a high proportion of concomitant PDAC and advanced stage, with P values of zero point zero zero three and less than zero point zero zero one.

Pancreatic carcinomas with aberrant CA19-9 elevation were also associated with high mortality compared with carcinomas without aberrant elevation. Table two cross-classifies one hundred patients by abnormal laboratory results and imaging findings when pancreatic carcinoma was diagnosed in the setting of IPMN.

Laboratory abnormalities were present in fifty-two patients, including thirty-nine with elevated CA nineteen-nine either alone or with other abnormalities, while forty-eight had no abnormal laboratory elevation. Imaging findings were reported as present for AUS, CT, MRI or MRCP, and EUS, but some patients had absent AUS findings or no imaging; the table shows how these imaging categories align with specific laboratory abnormalities.

Figure four tracks morphologic changes in IPMNs before pancreatic carcinoma diagnosis, separating IPMN-derived carcinomas from concomitant pancreatic ductal adenocarcinomas. Each horizontal trajectory marks latency to malignancy, while colors identify high-risk stigmata, worrisome features, or no such feature; adjacent columns show age, sex, main-duct size, and cancer stage.

The visual matters because it reveals how the timing and visibility of these warning features differ by carcinoma type and stage, supporting the authors’ finding that stage zero-to-two concomitant tumors often show fewer features before diagnosis. Figure 4 illustrates longitudinal changes of morphological features of IPMNs among patients with IPMN-derived and concomitant carcinomas, according to cancer stage.

The study separately summarized the types and timing of worrisome features and high-risk stigmata observed during surveillance, and the types eventually present at carcinoma diagnosis. At least one worrisome feature or high-risk stigma developed in all patients but one with a concomitant carcinoma.

Compared with IPMN-derived carcinomas, concomitant PDACs were less likely to represent high-risk stigmata: sixteen percent versus eighty-six percent, with P less than zero point zero zero one. Worrisome features and high-risk stigmata were less likely to be observed before the clinical manifestation of stage zero to two concomitant PDACs.

The time from documenting a worrisome feature or high-risk stigma to carcinoma diagnosis was significantly shorter for concomitant PDACs: zero point two years versus one point six years for IPMN-derived carcinomas. Table 3 compares carcinoma type and stage across three CA19-9 trajectory patterns during IPMN surveillance: aberrant elevation, high to high, and low to low.

Among the aberrant-elevation group, 25 cases, or 60 percent, were concomitant PDAC, while 14, or 30 percent, were IPMN-derived carcinoma; the type comparison had a P value of zero point zero zero three. Stage distributions also differed, with nine stage three and nine stage four cases in the aberrant-elevation group, and the overall stage comparison reported P less than zero point zero zero one.

The study found that aberrant serum CA19-9 elevation occurred in up to sixty percent of patients developing concomitant PDACs, but less frequently in patients developing IPMN-derived carcinomas. Carcinomas with CA19-9 elevation were reliably detected by contrast-enhanced CT or MRI, which casts doubt on using CA19-9 alone for surveillance.

HbA1c rarely elevated before carcinogenesis, while pancreatic enzyme elevation occurred in eighteen percent and clinically evident pancreatitis in only five percent. The carcinoma types also showed distinctive morphological patterns: concomitant PDACs frequently arose without the high-risk stigmata characteristic of IPMN-derived carcinomas.

The study points to limited potential for blood biomarkers in early diagnosis of incidental PDAC, even though CA19-9 is widely used for postoperative surveillance and tumor burden monitoring during chemotherapy. In this study, serum CA19-9 had limited sensitivity and specificity during long-term cancer monitoring of patients with IPMNs.

Abnormal imaging findings appeared when aberrant CA19-9 elevation was observed, questioning whether CA19-9 can detect cancer at a preclinical stage when no mass lesion is present. The discussion emphasizes careful evaluation of follow-up MRI and suggests incorporating EUS into surveillance for patients with main pancreatic duct dilatation who are at high risk.

The study has several limitations. Its dataset came from patients diagnosed with IPMNs at a single tertiary referral center, which could produce selection bias. Blood tests and imaging occurred at varying times and intervals between patients, so the time from the last surveillance examination to clinical diagnosis might depend on that interval.

A vast majority of the study population was Japanese, so the findings should be validated in independent cohorts. The long-term data indicate limited ability of currently available blood biomarkers to identify early-stage pancreatic carcinomas during IPMN surveillance, particularly IPMN-derived carcinomas.

A diagnostic approach based on the distinctive morphological patterns of IPMN-derived carcinomas might also be infeasible for detecting concomitant PDACs. Further research is warranted on multidisciplinary surveillance strategies integrating liquid-based biomarker engineering and imaging analysis.

In this prospective series, blood markers were limited for finding early cancer, while imaging changes differed by cancer type. Concomitant PDAC often lacked high-risk stigmata, pointing toward better biomarkers and imaging surveillance.